154 related articles for article (PubMed ID: 11762344)
1. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Gorzegno G; Bollito E; Mari M; Tarabuzzi R; Poggio M; Torta M; Fontana D; Angeli A
Ann Oncol; 2001; 12 Suppl 2():S153-7. PubMed ID: 11762344
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
3. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
[TBL] [Abstract][Full Text] [Related]
4. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
5. Circulating neuroendocrine markers in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Bellina M; Mari M; Torta M; Tarabuzzi R; Bollito E; Fontana D; Angeli A
Cancer; 2000 Jun; 88(11):2590-7. PubMed ID: 10861438
[TBL] [Abstract][Full Text] [Related]
6. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
7. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
Bollito E; Berruti A; Bellina M; Mosca A; Leonardo E; Tarabuzzi R; Cappia S; Ari MM; Tampellini M; Fontana D; Gubetta L; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S159-64. PubMed ID: 11762345
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
9. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
11. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
[TBL] [Abstract][Full Text] [Related]
12. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
[TBL] [Abstract][Full Text] [Related]
13. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
16. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
17. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate.
Deftos LJ; Nakada S; Burton DW; di Sant'Agnese PA; Cockett AT; Abrahamsson PA
Urology; 1996 Jul; 48(1):58-62. PubMed ID: 8693652
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A--serum marker for prostate cancer.
Khan MO; Ather MH
J Pak Med Assoc; 2011 Jan; 61(1):108-11. PubMed ID: 22368921
[TBL] [Abstract][Full Text] [Related]
19. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO
J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
[TBL] [Abstract][Full Text] [Related]
20. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.
Wu JT; Astill ME; Liu GH; Stephenson RA
J Clin Lab Anal; 1998; 12(1):20-5. PubMed ID: 9484665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]